This week's roundup of Houston innovators includes Samra Nawaz of WellWorth, Michael Suffredini of Axiom Space, and Colin McLelland of Digital Wildcatters. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries recently making headlines in Houston across energy and space tech.

Samra Nawaz, CEO and co-founder of WellWorth

Samra Nawaz founded WellWorth to tackle the convoluted financial modeling process in upstream oil and gas. Photo courtesy of WellWorth

As much as she loves a good Excel spreadsheet, Samra Nawaz had just about had it with the convoluted — and not always completely accurate — process of building financial models within upstream oil and gas.

"Excel is generally a good tool to automate workflows and build really robust spreadsheets. I live in Excel — I have a spreadsheet for everything," Nawaz says on the Houston Innovators Podcast. "What Excel is not is a database."

Engineering teams work with massive amounts with data that's too big for Excel, she explains, so finance teams then have to work off of aggregated data to build their financial models. She was ranting about why there isn't a better process to her husband, Vinay Acharya, who suggested that they build it themselves. Read more.


Michael Suffredini, CEO of Axiom Space

Axiom Space CEO Michael Suffredini has opened the company's new HQ in the Houston Spacepory. Photo courtesy of Axiom Space

Axiom Space, co-founded by CEO Michael Suffredini, has opened its new Assembly Integration and Test Building, which will be the new headquarters for the Houston-based aerospace company at a new 22-acre campus at the Houston Spaceport at Ellington Airport in Southeast Houston. The building will include employee offices, facilities for astronaut training and mission control, testing labs and a high bay production facility to house Axiom Space Station modules currently under construction.

Axiom Space partnered with Jacobs, Turner Construction Company, Savills, and Griffin Partners to expand the company’s headquarters with the Houston spaceport building, which is the tenth spaceport in the nation.

For the first time in Houston’s history, the Space City is now home to the development of human-rated spacecraft with the Axiom Stations modules. Houston Spaceport has laboratory office space like technology incubator space and large-scale hardware production facilities, and is the world’s first urban commercial spaceport. Read more.

Collin McLelland, co-founder and CEO of Digital Wildcatters

Collin McLelland, co-founder and CEO of Digital WildcattersThis Houston-based media company launched a networking platform to help solve the energy crisis. Photo courtesy

Digital Wildcatters, a Houston company that's providing a community for the next generation of energy professionals, has closed its seed plus funding round at $2.5 million. The round by energy industry veteran Chuck Yates, who also hosts his podcast "Chuck Yates Needs a Job" on the Digital Wildcatters' podcast network.

"Our mission is to empower the next generation of energy professionals to advance their careers and collaboratively address the global energy crisis," Collin McLelland, co-founder and CEO of Digital Wildcatters, says in the release. "We are incredibly grateful to have an investor base that not only believes in our vision but also supports our endeavor to craft innovative products that will redefine the future of the energy industry." Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”